2021
Update on Osteoporosis Screening and Management
Anam AK, Insogna K. Update on Osteoporosis Screening and Management. Medical Clinics Of North America 2021, 105: 1117-1134. PMID: 34688418, DOI: 10.1016/j.mcna.2021.05.016.ChaptersConceptsLimited alcohol intakeNew anabolic therapiesLow bone massDual-energy X-ray absorptiometry measurementsBone mineral densityMetabolic bone diseasePostmenopausal womenAnabolic therapyFragility fracturesMicroarchitectural deteriorationSevere osteoporosisBone healthAlcohol intakeOsteoporosis screeningSmoking cessationVitamin DMineral densityPharmacologic agentsBone massBone diseaseHigh riskAbsorptiometry measurementsGold standardOsteoporosisBone tissue
2009
Dominant role of CD47–thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease
Kukreja A, Radfar S, Sun BH, Insogna K, Dhodapkar MV. Dominant role of CD47–thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood 2009, 114: 3413-3421. PMID: 19661269, PMCID: PMC2765677, DOI: 10.1182/blood-2009-03-211920.Peer-Reviewed Original ResearchConceptsHuman dendritic cellsDendritic cellsBone diseaseOsteoclast formationRecruitment of DCsTumor cellsThrombospondin-1Regulation of CD47Tumor-associated osteoclastsNuclear factor-kappaB ligandMyeloma bone diseaseLytic bone diseasePrimary myeloma cellsHuman osteoclast formationMyeloma cell linesParathyroid hormoneKappaB ligandReceptor activatorOsteoclast precursorsGiant cellsSpontaneous cell-cell fusionMyeloma cellsHuman monocytesMyeloma tumorsDiseaseLDL-Receptor Related Protein Five Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum
Yadav V, Ryu J, Suda N, Tanaka K, Gingrich J, Schütz G, Glorieux F, Chiang C, Zajac J, Insogna K, Mann J, Hen R, Ducy P, Karsenty G. LDL-Receptor Related Protein Five Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Obstetrical & Gynecological Survey 2009, 64: 240-242. DOI: 10.1097/01.ogx.0000345723.85624.24.Peer-Reviewed Original ResearchLDL receptor-related protein 5Function mutationsHigh bone mass syndromeTryptophan hydroxylase 1Bone massSerotonin synthesisGene deletion experimentsBone formationLrp5 lossEnterochromaffin cellsMajor regulatory roleMass syndromeBone diseaseVertebrate homologsOsteoporosis pseudogliomaTranscriptional effectorsWnt proteinsBiosynthetic enzymesDeletion experimentsRegulatory roleRare bone diseasesProtein 5Rate-limiting biosynthetic enzymeMutationsLRP5 gain
1996
24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets--a clinical research center study
Carpenter TO, Keller M, Schwartz D, Mitnick M, Smith C, Ellison A, Carey D, Comite F, Horst R, Travers R, Glorieux FH, Gundberg CM, Poole AR, Insogna KL. 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets--a clinical research center study. The Journal Of Clinical Endocrinology & Metabolism 1996, 81: 2381-2388. PMID: 8964881, DOI: 10.1210/jcem.81.6.8964881.Peer-Reviewed Original ResearchConceptsD3 supplementationStandard treatmentSkeletal lesionsClinical research center studyCorrection of hyperparathyroidismImprovement of ricketsPlacebo-controlled trialD supplementationRachitic abnormalitiesNephrogenous cAMPPTH secretionStandard therapyPTH valuesSerum phosphorusCenter studyRadiographic featuresBone biopsyOsteoid surfaceBone diseaseMurine modelHypophosphatemic ricketsUseful adjunctCalcium homeostasisHyperparathyroidismXLH